Efficacy, safety data support use of lisocabtagene maraleucel at community sites
Click Here to Manage Email Alerts
NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.
Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — a CD19-directed chimeric antigen receptor T-cell therapy often referred to as liso-cel — demonstrated clinical activity with a manageable safety profile among both inpatients and outpatients regardless of prior hematopoietic stem cell transplantation, findings presented at ASH Annual Meeting and Exposition showed.
Healio spoke with researcher Michael B. Maris, MD, medical director of research at Colorado Blood Cancer Institute, about the study results and their potential implications.
Collapse
Linhares Y, et al. Abstract 4673. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Click Here to Manage Email Alerts